WITHDRAWN STUDY STATEMENT

Sponsor: Teva Pharmaceutical Industries, Ltd.

Title of Study: A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Control (Rater Blinded) Study, to Evaluate the Efficacy, Safety and Tolerability of 2 Doses of Oral administration of Laquinimod (0.6 mg/day or 1.2 mg/day) compared to Interferon β-1a administered Intra Muscular Once Weekly in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS)

Study Number: LAQ-MS-306

EudraCT Number: 2013-002082-19

Investigational Product: Laquinimod (TV-5600)

Phase: 3

Statement: This study was registered in the EudraCT database. However, due to a change in plans for development the sponsor made the decision to terminate the study before any participants were randomized. Therefore, no results are available.